EUVIMEDOpdag EUVIMED
Übersichtsarbeit

PCSK9 as a Regulatory Network: Molecular Mechanisms, Therapeutic Targeting, and Herbal Modulation

Putri Cahaya Situmorang iD, Cheryl Grace Pratiwi Rumahorbo iD, Rony Abdi Syahputra iD, Etti Sartina Siregar, Alberico Catapano

Cell Biology International · 2026-11 · 50 (11)

DOI: 10.1002/cbin.70232 ↗

At a glance

Übersichtsarbeit in Cell Biology International, published online on 2026-11-10. Written by Putri Cahaya Situmorang and 4 co-authors. Institution: Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia. Major MEDLINE topics: Proprotein Convertase 9. 127 references. Funded by: EQUITY-LPDP Research, TALENTA-Universitas Sumatera Utara.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a central regulator of cholesterol homeostasis through its role in promoting low‐density lipoprotein receptor (LDLR) degradation and limiting hepatic low‐density lipoprotein cholesterol (LDL‐C) clearance. The clinical success of monoclonal antibodies and small interfering RNA (siRNA)‐based therapies has established PCSK9 as an important therapeutic target. However, PCSK9 biology extends beyond its canonical role in LDLR degradation, with its expression and activity regulated through interconnected transcriptional, post‐transcriptional, metabolic, and intracellular signaling mechanisms involving sterol regulatory element‐binding protein‐2 (SREBP‐2), hepatocyte nuclear factor‐1α (HNF‐1α), microRNAs, and multiple signaling pathways. This regulatory complexity is illustrated by compensatory responses, including statin‐induced PCSK9 expression, and by observations that changes in PCSK9 expression do not always directly predict overall metabolic outcomes. Current therapeutic strategies primarily target circulating PCSK9 or suppress its hepatic synthesis, whereas upstream and multi‐level regulatory mechanisms remain less extensively explored. Herbal‐derived compounds have emerged as potential multi‐target modulators of the PCSK9 regulatory network, with experimental studies indicating that phytochemicals and plant extracts may influence PCSK9 through coordinated effects on transcriptional regulators, cellular signaling pathways, and LDLR expression. Nevertheless, the available evidence is heterogeneous, with substantial variation in experimental models, phytochemical composition, dosing strategies, and mechanistic endpoints. This review integrates current evidence on the molecular regulation of PCSK9, established and emerging therapeutic strategies, and herbal modulation across in vitro, in vivo, and in silico studies. Overall, the evidence supports a network‐based interpretation of PCSK9 regulation and suggests that multi‐target herbal modulation may provide a complementary strategy to conventional PCSK9‐directed therapies by acting at multiple regulatory levels. However, the predominantly preclinical nature of the available evidence underscores the need for standardized phytochemical characterization, rigorous mechanistic validation, and well‐designed clinical studies before therapeutic translation can be established.

Subjects

MeSH terms (MEDLINE)

Proprotein Convertase 9HumansAnimalsSignal TransductionReceptors, LDLPhytochemicalsPCSK9 Inhibitors

Author keywords

LDL receptor (LDLR)PCSK9herbal modulationmicroRNAnetwork reprogrammingphytochemicals

Substances

Proprotein Convertase 9PCSK9 protein, humanReceptors, LDLPhytochemicalsPCSK9 Inhibitors

Authors and institutions

  • Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, Indonesia.
  • Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, Indonesia.
  • Department of Pharmacological and Biomolecular Sciences, Faculty of Pharmacy, Università degli Studi di Milano, Milan, Italy.

ORCID profiles: Putri Cahaya Situmorang, Cheryl Grace Pratiwi Rumahorbo, Rony Abdi Syahputra

Funding

  • EQUITY-LPDP Research
  • TALENTA-Universitas Sumatera Utara

Cite

APA

Situmorang, P. C., Rumahorbo, C. G. P., Syahputra, R. A., Siregar, E. S., & Catapano, A. (2026). PCSK9 as a Regulatory Network: Molecular Mechanisms, Therapeutic Targeting, and Herbal Modulation. Cell Biology International, 50(11). https://doi.org/10.1002/cbin.70232

Vancouver

Situmorang PC, Rumahorbo CGP, Syahputra RA, Siregar ES, Catapano A. PCSK9 as a Regulatory Network: Molecular Mechanisms, Therapeutic Targeting, and Herbal Modulation. Cell Biology International. 2026;50(11). doi:10.1002/cbin.70232

BibTeX
@article{Situmorang2026,
  author = {Situmorang, Putri Cahaya and Rumahorbo, Cheryl Grace Pratiwi and Syahputra, Rony Abdi and Siregar, Etti Sartina and Catapano, Alberico},
  title = {PCSK9 as a Regulatory Network: Molecular Mechanisms, Therapeutic Targeting, and Herbal Modulation},
  journal = {Cell Biology International},
  year = {2026},
  volume = {50},
  number = {11},
  doi = {10.1002/cbin.70232}
}
Start for free →